A Multi-center, double-masked, randomized, placebo-controlled, ascending dose study of INS115644 ophthalmic solution in subjects with bilateral ocular hypertension or early open angle glaucoma.


Principal Investigator 

Robert Ritch, M.D.

Objective

Evaluate the safety and efficacy of the new drug Latrunculin.

Eligibility

Over 40 years old, diagnosed with Primary Open Angle Glaucoma or Ocular Hypertension. No intraocular surgeries besides cataract surgery.

Enrollment Goal

15 participants (OPEN)

Contact Information

John Purcell
(212) 477-7540 Ext. 302

 

Home > Current Research > Clinical Trials in Ophthalmology > A Multi-center, double-masked, randomized, placebo-controlled, ascending dose study of INS115644 ophthalmic solution in subjects with bilateral ocular hypertension or early open angle glaucoma.